Actively Recruiting
Randomized, Double-blind Study of Nefecon 8 mg Daily to Prevent Relapse in IgA Nephropathy Patients After Proteinuria Remission
Led by Nanfang Hospital, Southern Medical University · Updated on 2026-09-02
288
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
IgA nephropathy IgAN is a chronic kidney disease where controlling proteinuria and preventing relapse are important to slow disease progression. This trial evaluates the use of Nefecon 8 mg as a maintenance therapy over 15 months in patients who have achieved proteinuria remission after previous treatment, aiming to reduce the risk of relapse. The study is a randomized, double-blinded, placebo-controlled Phase 4 trial focused on treatment of IgAN. Participants are randomly assigned to receive either Nefecon 8 mg or a placebo once daily by mouth for 15 months. The study compares these two groups to assess the efficacy and safety of continued Nefecon treatment after an initial longer course. Patients must have completed at least 9 months of Nefecon 16 mg before starting this maintenance phase, and their proteinuria levels must be low at screening. During the study, participants will have regular assessments including measurements of kidney function, proteinuria levels, and adverse events over the 15-month treatment period. The main outcome is the time to first disease relapse, with additional measures including kidney filtration rate changes, proteinuria levels, major kidney events, and mortality. The trial also monitors safety and overall health throughout the study duration.
CONDITIONS
Brief Title
Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy
Research Team
F
Fan Fan Hou
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here